The term acute respiratory distress syndrome (ARDS) was first coined in 1967
|
|
- Silas West
- 7 years ago
- Views:
Transcription
1 AACN Advanced Critical Care Volume 26, Number 3, pp AACN Earnest Alexander, PharmD, and Gregory M. Susla, PharmD Department Editors Pharmacological Treatments for Acute Respiratory Distress Syndrome Melissa Chudow, PharmD Michelle Carter, PharmD Mark Rumbak, MD The term acute respiratory distress syndrome (ARDS) was first coined in 1967 to define a clinical syndrome categorized by progressive hypoxemia, dyspnea, and increased work of breathing that is unresponsive to standard respiratory therapy. 1 Acute respiratory distress syndrome presents as acute respiratory failure with noncardiogenic pulmonary edema and severe hypoxemia. 2 Historically, this syndrome of potentially fatal pulmonary complications described in critically ill patients was further divided into acute lung injury (ALI) and ARDS, with ALI representing a more mild presentation of ARDS. 2 More recently, the concept of ALI has been replaced with mild, moderate, and severe classifications for ARDS. 3 Despite the substantial progress made in understanding the mechanism of this disease process, ARDS continues to be a major clinical concern. The estimated prevalence in the intensive care unit (ICU) ranges from 4% to 9%, with up to 50% of patients with mild ARDS progressing to moderate or severe forms of the disease. Acute respiratory distress syndrome is associated with substantial mortality rates as high as 46%. 2, 4 In addition, ARDS is a major contributor to health care costs, with approximately $ to $ spent treating each episode. 2 Prompt recognition of the clinical syndrome and initiation of management strategies are required to minimize mortality and improve outcomes in affected individuals. 5 This article provides an overview of ARDS with a specific focus on current and evolving pharmacological treatment strategies for this potentially devastating disease state. Diagnosis and Causes The most recent representation of the ARDS diagnostic criteria is reflected in the Berlin definition, which was updated in 2011 from the original definition developed in 1994 by the American European Consensus Conference on ARDS. 3 According to the Berlin definition, for a diagnosis of ARDS to be confirmed, the disease state must be characterized by acute onset of bilateral infiltrates evident on chest radiograph and a pulmonary artery wedge pressure of 18 mm Hg or less with no clinical evidence of left atrial hypertension. The degree of severity Melissa Chudow is PGY-2 Critical Care Pharmacy Resident, Department of Pharmacy Services, Tampa General Hospital, PO Box #1289, Tampa, FL ( mchudow@tgh.org ). Michelle Carter is Clinical Pharmacist, Department of Pharmacy Services, Tampa General Hospital, Tampa, Florida. Mark Rumbak is Division Director, Pulmonary, Critical Care, and Sleep Medicine, Morsani College of Medicine, University of South Florida, Tampa. The authors declare no conflicts of interest. DOI: /NCI
2 Drug Update is categorized into 3 stages on the basis of hypoxemia as evidenced by the ratio of partial pressure of oxygen (Pa o 2 ) to fraction of inspired oxygen (F Io 2 ): mild (200 mm Hg Pa o 2 /F Io mm Hg), moderate (100 mm Hg Pa o 2 /F Io mm Hg), and severe (Pa o 2 /F Io mm Hg). The Berlin definition addresses limitations provided in the American European Consensus Conference, resulting in a better predictor of validity of mortality. 3 The potential cause of ARDS can be attributed to direct or indirect causes. Direct risk factors for lung injury include pneumonia, aspiration of gastric contents, pulmonary contusion, fat or air emboli, inhalation injury, and reperfusion injury. Indirect lung injury occurs secondary to sepsis, severe trauma, cardiopulmonary bypass, toxic ingestions, acute pancreatitis, or transfusion of blood products. 6 Pneumonia and sepsis are the most common causes of direct and indirect lung injury, respectively. 2 Pathophysiology and Clinical Course Acute respiratory distress syndrome can be characterized by 3 progressive clinical stages, the exudative, proliferative, and fibrotic phases ( Table 1 ). The lungs move through this series of phases, regardless of the initial cause of the lung injury. 7 The specific time frames associated with each phase vary considerably in the existing literature. In the initial exudative phase, also called the acute phase, widespread damage to the alveolar epithelium is present. The compromised epithelium increases the permeability of the alveolar-capillary barrier allowing fluid, rich in protein, to accumulate in the alveoli. 8 Continued damage to the epithelium occurs secondary to release of proinflammatory mediators. Cytokines recruit neutrophils to the lungs, causing production of reactive oxygen species and proteases. Alveolar damage and impairment of surfactant production ultimately causes alveolar collapse and impaired gas exchange. 2 During the proliferative stage, also known as the subacute phase, the pulmonary edema seen in the exudative phase begins to resolve. 4 During this time, the membranes within the alveoli have become overwhelmed by plasma proteins, fibrin, and cellular debris. Multiple detrimental pathways are activated causing impaired surfactant production, enhanced neutrophil activation, and stimulation of the complement and coagulation cascades. 2, 9 Type II alveolar cells proliferate during this phase, which is the body s initial attempt to repair the lung injury. 8 Unfortunately, the inflammatory mediators produced within the lungs commonly migrate into the bloodstream causing cellular apoptosis in other organs. Mortality is often not associated with hypoxemia or hypercapnia but rather from multisystem organ dysfunction. 9 The fibrotic, or chronic, phase is the final stage of ARDS. Not all patients progress to the later stages of the disease process, as some experience an uncomplicated course and recover quickly. Collagen deposition leads to pulmonary fibrosis, which is the hallmark feature of late-stage ARDS. 2 Fibrosis can compromise the pulmonary vascular area by destroying alveoli and commonly leads to chronic inflammation. 9 Recovery from ARDS begins to occur as a result of a rise in alveolar type II cells, which promote fluid removal. Type II cells begin to differentiate into type I cells returning the epithelial layer to normal and ultimately providing disease resolution. 2 Pharmacological Treatment Strategies Treatment of ARDS occurs through a combination of strategies that attempt to reduce pulmonary edema while reversing oxygen-exchange issues. 10 The only treatment option that has shown to reduce mortality rates is lung-protective mechanical ventilation. 7 A multitude of different pharmacological agents have been investigated for the treatment of ARDS with most failing to show consistent clinical benefit. Deciding on a management strategy for these patients can be challenging, because of the complexity of the disease and conflicting existing evidence. 11 Although the most important aspect in the treatment of ARDS is lung-protective mechanical ventilation, this column focuses on the pharmacological options that can assist in the supportive management of this disease process ( Table 2 ). Corticosteroids Corticosteroids have been studied for years in the prevention and treatment of ARDS because of the anti-inflammatory and immunomodulatory characteristics they exhibit. Beneficial effects are due to inhibition of the inflammatory cascade at different stages of immune-mediated injury to the lung. Glucocorticoids inhibit the NF- κ B signaling pathway, which in turn inhibits interleukin 1, interleukin 6, and tumor necrosis factor α, which are all inflammatory mediators in the process of ARDS. 12 In addition, steroids inhibit interleukin 186
3 Drug Update Table 1: Clinical Phases of Acute Respiratory Distress Syndrome a Stage Approximate Time Frame Characteristics Exudative Days 1-6 Injury to the endothelium and epithelium with increased permeability Accumulation of fluid in alveoli Accumulation of inflammatory markers in lungs Proliferative Days 7-14 Reabsorption of pulmonary fluid overload Proliferation of type II alveolar cells Intensification of inflammatory and coagulation pathways Fibrotic After day 14 Repair of alveolar epithelium Pulmonary fibrosis caused by collagen deposition a Developed from the studies by Shafeeq and Lat 2 and Matthay and Zemans. 8 3, interleukin 5, and interleukin 8 while amplifying the antifibrotic properties of cortisol, promoting T-cell stimulation, impairing fibroblast proliferation, and minimizing collagen deposition. Potential benefit must be weighed against possible risks, including hyperglycemia, impaired wound healing, enhanced susceptibility to future infections, and extended muscle weakness. 2 Corticosteroids have been studied in the different phases of ARDS and are most efficacious in the early and late phases. Many randomized clinical trials have shown a decrease in ICU mortality rate, ventilation days, and inflammatory markers In the latest study by Meduri et al, 17 low-dose methylprednisolone administered in the first 72 hours after ARDS diagnosis resulted in reduced days on mechanical ventilation and in the ICU. In an earlier study, Steinberg et al 16 used a moderate dose of methylprednisolone started 7 to 28 days after the diagnosis of ARDS. This study showed that although methylprednisolone increased the number of ventilator-free days, the mortality rates were comparable between groups. As clinical trials evolve, the trend continues to show beneficial results in ARDS with treatment of corticosteroids. In 2008, the Society of Critical Care Medicine published the latest recommendations for the use of corticosteroids in the treatment of ARDS. 12 Moderate-dose glucocorticoid, defined as methylprednisolone 1 mg/kg as a load over 30 minutes followed by 1 mg/kg over 24 hours per day via continuous infusion for 14 days with slow-dose tapering, is recommended. 12 Neuromuscular Blocking Agents Neuromuscular blocking agents are commonly used in patients with severe gas-exchange deficiencies to facilitate mechanical ventilation when sedation is insufficient. 18 Skeletal muscle inhibition produced through the use of neuromuscular blocking agents eliminates patient effort in the breathing process. 19 Facilitation of paralysis helps reduce the risk of ventilatorinduced injury by improving chest wall compliance, preventing patient-ventilator dyssynchrony, minimizing inflammatory mediator release, reducing overinflation of the lungs, and decreasing oxygen demand. 18 Cisatracurium has the most extensive evidence supporting its short-term use with small-scale, randomized, controlled trials demonstrating improved 90-day survival, reduced mechanical ventilation time, and decreased days with documented organ failure. 18 However, older studies have reported conflicting evidence describing that the use of neuromuscular blocking agents may potentially be associated with prolonged neuromuscular weakness that may make weaning ventilation more challenging. 4 Inhaled Vasodilators Inhaled vasodilators, including nitric oxide and prostacyclins, selectively lead to vasodilation within the pulmonary vasculature that assists in improving oxygenation status without substantial adverse effects on systemic hemodynamics. Nitric oxide dilates the vasculature by increasing conversion to cyclic guanosine monophosphate resulting in smooth muscle relaxation. 10 Prostacyclins, such as epoprostenol and alprostadil, act on the prostaglandin receptors to increase levels of cyclic adenosine monophosphate to cause relaxation of the vasculature. 10 The vasodilation produced by these agents also may lead to other beneficial pulmonary and cardiovascular effects, including reduced pulmonary vascular resistance, minimized right ventricular afterload, and increased right ventricular stroke volume. 10 In addition, nitric oxide may impede 187
4 Drug Update Table 2: Summary of Pharmacological Treatment Options for Acute Respiratory Distress Syndrome a Class Commonly Studied Agents Dosing Potential Beneficial Outcome Significant Adverse Effects Monitoring Parameters Corticosteroids Methylprednisolone 1 mg/kg per day Decreased ICU mortality rate, ventilation days, and inflammatory markers Hyperglycemia, impaired wound healing, enhanced susceptibility to infections, muscle weakness Blood pressure, blood glucose, electrolytes Neuromuscular blocking agents Cisatracurium Bolus: mg/kg Continuous: g/kg per minute Reduced mortality rates, ventilation days, and days with organ failure Prolonged neuromuscular weakness Twitch response measured by peripheral nerve stimulation, level of sedation Inhaled vasodilators Nitric oxide b 5-20 ppm Improved oxygenation status Inhaled formulation generally safe, rare methemoglobinemia, bleeding events, kidney injury Arterial blood gas, oxygen saturation, methemoglobin Epoprostenol b 0.05 g/kg per minute Irritation of trachea, bleeding events Oxygen saturation, heart rate Exogenous surfactant replacement Beractant b 100 mg lipids/kg Improved oxygenation status Bradycardia Heart rate β -Adrenergic agonists Salbutamol b 2 (albuterol) 15 g/kg per hour Lower lung water content and plateau pressure Vasodilatory effects, tachycardia, cardiac ischemia Heart rate, blood pressure Anti-inflammatory agents Ketoconazole b mg daily May help prevent development of ARDS Drug interactions, hepatic injury Liver function tests Antioxidants N -acetylcysteine b 1-10 ml of 20% or 2-20 ml of 10% every 2-6 h Improvement in lung injury scores Generally well-tolerated Allergic reaction Abbreviations: ARDS, acute respiratory distress syndrome; ICU, intensive care unit; ppm, parts per million. a Developed from references 2, 4, and 9 to 20. b Off-label use. 188
5 Drug Update neutrophil and platelet activation seen in acute inflammation. 7 Prostacyclins are increasingly becoming the vasodilator of choice due to lower cost compared with nitric oxide. 4 Existing evidence demonstrates that inhaled vasodilators have not been associated with reduced ventilator days or mortality rates. However, this inhaled therapy may be beneficial in improving oxygenation, so it should be considered in patients with refractory 10, 20 hypoxemia. Exogenous Surfactant Replacement The body s natural surfactant supply is composed of 90% lipids and 10% protein and is responsible for preventing alveolar collapse by reducing surface tension within the lung. In addition, surfactant possesses anti-inflammatory properties, enhances phagocytic cell activity, and scavenges free oxygen radical species. Because of the disruption in the endogenous surfactant system in ARDS, the administration of exogenous surfactant appears to be a reasonable treatment strategy. Surfactant was originally administered as an aerosolized product, but tracheal instillation is now preferred because of concerns over low levels of alveolar deposition with the aerosolized formulation. 9 Use of surfactant has not been shown to have beneficial effects on mortality rates or ventilator-free days, but oxygenation status was improved. 20 Efficacy of exogenous surfactant may be questionable because synthetic products may be easily inactivated in the lungs and large volumes are needed to cover the lung surface area. 11 Because of the widespread benefit seen in pediatric lung injury trials, further investigation of the use of exogenous surfactant in adult ARDS is warranted. 20 β 2 -Adrenergic Agonists β 2 -Adrenergic agonists can enhance fluid clearance from the alveolar space. 20 These agents increase sodium and chloride transport across the epithelial membrane via the Na + /K + ATPase pump, which subsequently causes water to move in the direction of the electrolyte shift. Two potential mechanisms have been proposed to explain β 2 -agonists effect on fluid clearance, including augmentation of intracellular cyclic adenosine monophosphate upregulating the Na + /K + ATPase pump and minimizing permeability between the alveolar-capillary barriers. 9 Beneficial effects may also be seen due to cytoprotection and reduced endothelial permeability. β 2 -Agonists have been evaluated through both the intravenous and inhaled routes in clinical trials with inhaled formulations demonstrating a superior adverse effect profile. The place in therapy of these agents may be limited because of the risk of detrimental cardiac side effects, including tachyarrhythmias and cardiac ischemia. 19 Ketoconazole In addition to antifungal properties, ketoconazole also may play a role in the treatment of ARDS because of its anti-inflammatory properties. Ketoconazole inhibits formation of thromboxane A 2, which is responsible for strong vasoconstriction. In addition, ketoconazole impairs production of leukotrienes, which, when they accumulate, attracts other proinflammatory mediators to the site of injury. 20 Release of cytokines from macrophages located within the alveoli also is hindered with the use of ketoconazole. Studies have shown that the use of ketoconazole may help prevent the development of ARDS, but it has no impact on the mortality rate in patients with established disease. Significant barriers impede routine use of ketoconazole in critically ill patients, including a multitude of drug interactions and the need for an acidic environment for absorption through the enteral route. 9 Antioxidants Antioxidant therapies have been proposed as a potential treatment strategy because reactive oxygen species, produced by neutrophils and macrophages, contribute to tissue damage in ARDS. N -acetylcysteine, which is traditionally used for acetaminophen overdoses, serves as a glutathione precursor. Glutathione is a natural antioxidant found in healthy lung tissue, but concentrations are depleted in patients with ARDS. 9 The use of enteral nutrition high in omega-3 fatty acids may provide an additional source of antioxidant supplementation. Vitamins E and C also can be provided to minimize oxidative stress caused by ARDS. 9 Overall, evidence suggests that antioxidant therapy likely offers no mortality benefit but may reduce the extent of lung injury. 11 Statins HMG (3-hydroxy-3-methyl-glutaryl) CoAreductase inhibitors, which are more commonly known as statins, possess multiple physiological benefits in addition to their ability to lower cholesterol level. Statins are thought to attenuate many underlying mechanisms that cause 189
6 Drug Update ARDS. In animal and human models, statin use has reduced local and systemic inflammatory processes as well as histological evidence of lung injury. 21 Recent large-scale, randomized clinical trials have not found any clinical benefit to the use of statins in ARDS. Lack of improvement in outcomes combined with a questionable safety profile has led to statins no longer being recommended for the treatment of 21, 22 ARDS. Emerging Treatment The emerging concept of regenerative medicine, including stem cell therapy and growth factors, can assist in the healing of damaged lung tissue. Contact between stem cells and the alveoli facilitates advantageous effects including antiinflammatory and immunomodulatory properties and may improve integrity of the endothelial barriers. 19, 23 Mesenchymal stem cells are considered low in their immunogenicity, which opens up the option for use in different disease states. Both animal and human models have shown potential benefit of mesenchymal stem cell therapy for ARDS. 23 The optimal route of delivery is still under investigation, with stem cells being administered directly into the lung in recent human models. 19 Keratinocyte growth factor (KGF) plays a pivotal role in repair of lung injury. Endogenous KGF assists in the proliferation of type II alveolar cells in ARDS, which are responsible for improving tissue repair. In addition, KGF may play a helpful role during the injury process of the disease by enhancing fluid clearance from the alveoli and minimizing endothelial permeability and edema. 12 Palifermin, an intravenous formulation of KGF, is being investigated in a phase II clinical trial. 24 Conversely, levels of vascular endothelial growth factor have been found to be higher than normal in patients with ARDS. This growth factor is associated with control of vascular permeability. Vascular endothelial growth factor inhibitors could be a potential future therapeutic option. 19 Conclusion Since the initial recognition of ARDS in 1967, substantial advancement has occurred in understanding the pathophysiology and treatment strategies for this disease process. Declining mortality rates in the past decades can be attributed to lung-protective ventilation combined with enhanced supportive measures, particularly corticosteroids and neuromuscular blocking agents. Because of the persistence of relatively high mortality rates and serious complications associated with ARDS, there continues to be significant effort in discovering pharmacological agents that improve clinical outcomes. In the coming years, we can expect that new treatment strategies will be investigated and available for use in the management of ARDS. REFERENCES 1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet ; 2 : Shafeeq H, Lat I. Pharmacotherapy for acute respiratory distress syndrome. Pharmacotherapy ; 32 ( 10 ): ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA ; 307 ( 23 ): Pierrakos C, Karanikolas M, Scolletta S, Karamouzos V, Velissaris D. Acute respiratory distress syndrome: pathophysiology and therapeutic options. J Clin Med Res ; 4 ( 1 ): Neamu RF, Martin GS. Fluid management in acute respiratory distress syndrome. Curr Opin Crit Care ; 19 ( 1 ): Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med ; 27 ( 4 ): Donahoe M. Acute respiratory distress syndrome: a clinical review. Pulm Circ ; 1 ( 2 ): Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol ; 6 : Bosma KJ, Taneja R, Lewis JF. Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: current and experimental approaches. Drugs ; 70 ( 10 ): Dzierba AL, Abel EE, Buckley MS, Lat I. A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome. Pharmacotherapy ; 34 ( 3 ): Kallet RH. Evidence-based management of acute lung injury and acute respiratory distress syndrome. Respir Care ; 49 ( 7 ): Marik PE, Pastores SM, Annane D, et al. American College of Critical Care Medicine. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med ; 36 ( 6 ): Meduri GU, Headley S, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA ; 280 : Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med ; 171 : Annane D, Sebille V, Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med ; 34 : Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med ; 354 : Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest ; 131 : Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? Crit Care Med ; 41 ( 5 ): Boyle AJ, Mac Sweeney R, McAuley DF. Pharmacological treatments in ARDS; a state-of-the-art update. BMC Med ; 11 :
7 Drug Update 20. Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med ; 21 ( 3 ): McAuley DF, Laffey JG, O Kane CM, et al ; HARP-2 Investigators; Irish Critical Care Trials Group. Simvastatin in the acute respiratory distress syndrome. N Engl J Med ; 371 ( 18 ): National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med ; 370 ( 23 ): Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res ; 15 : Cross LJ, O Kane CM, McDowell C, Elborn JJ, Matthay MA, McAuley DF. Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction a randomised placebocontrolled trial (KARE): study protocol. Trials ; 14 :
ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) S. Agarwal, MD, S. Kache MD
ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) S. Agarwal, MD, S. Kache MD Definition ARDS is a clinical syndrome of lung injury with hypoxic respiratory failure caused by intense pulmonary inflammation that
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More informationPharmacology of the Respiratory Tract: COPD and Steroids
Pharmacology of the Respiratory Tract: COPD and Steroids Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationInflammation and Healing. Review of Normal Defenses. Review of Normal Capillary Exchange. BIO 375 Pathophysiology
Inflammation and Healing BIO 375 Pathophysiology Review of Normal Defenses Review of Normal Capillary Exchange 1 Inflammation Inflammation is a biochemical and cellular process that occurs in vascularized
More informationSeptic Shock: Pharmacologic Agents for Hemodynamic Support. Nathan E Cope, PharmD PGY2 Critical Care Pharmacy Resident
Septic Shock: Pharmacologic Agents for Hemodynamic Support Nathan E Cope, PharmD PGY2 Critical Care Pharmacy Resident Objectives Define septic shock and briefly review pathophysiology Outline receptor
More informationLecture one lung pathology 4 th year MBBS. Dr Asgher Khan Demonstrator of pathology Rawalpindi Medical College Rwp.
Lecture one lung pathology 4 th year MBBS Dr Asgher Khan Demonstrator of pathology Rawalpindi Medical College Rwp. Expectation at end of lecture Brief review of anatomy and physiology related to lungs
More informationANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol
ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Isoproterenol Major Indications Status Asthmaticus As a last resort for
More informationPulmonary interstitium. Interstitial Lung Disease. Interstitial lung disease. Interstitial lung disease. Causes.
Pulmonary interstitium Interstitial Lung Disease Alveolar lining cells (types 1 and 2) Thin elastin-rich connective component containing capillary blood vessels Interstitial lung disease Increase in interstitial
More informationInotropes/Vasoactive Agents Hina N. Patel, Pharm.D., BCPS Cathy Lawson, Pharm.D., BCPS
Inotropes/Vasoactive Agents Hina N. Patel, Pharm.D., BCPS Cathy Lawson, Pharm.D., BCPS 1. Definition -an agent that affects the contractility of the heart -may be positive (increases contractility) or
More informationThe Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy
The Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy Cindy Goodrich RN, MS, CCRN Content Description Sepsis is caused by widespread tissue injury and systemic inflammation resulting
More informationThe Berlin definition of Severe ARDS includes assessment of which of the following?
2013 ACS Critical Care Update ARDS, Ventilators MCQs August, 2013 (Berlin Definition of ARDS Question 1) The Berlin definition of Severe ARDS includes assessment of which of the following? A. Oxygenation:
More informationPlease answer the following questions before reading the tutorial. The answers are contained in the article.
ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) Author Dr D. Lacquiere Correspondence: david_lacquiere@hotmail.com Please answer the following questions before reading the tutorial. The answers are contained
More informationRecommendations: Other Supportive Therapy of Severe Sepsis*
Recommendations: Other Supportive Therapy of Severe Sepsis* K. Blood Product Administration 1. Once tissue hypoperfusion has resolved and in the absence of extenuating circumstances, such as myocardial
More informationTACO vs. TRALI: Recognition, Differentiation, and Investigation of Pulmonary Transfusion Reactions
TACO vs. TRALI: Recognition, Differentiation, and Investigation of Pulmonary Transfusion Reactions Shealynn Harris, M.D. Assistant Medical Director American Red Cross Blood Services Southern Region Case
More informationVasopressors. Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco
Vasopressors Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco Overview Define shock states Review drugs commonly used to treat hypotension
More informationUnderstanding Hypoventilation and Its Treatment by Susan Agrawal
www.complexchild.com Understanding Hypoventilation and Its Treatment by Susan Agrawal Most of us have a general understanding of what the term hyperventilation means, since hyperventilation, also called
More information9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance
Disclosure Statement of Financial Interest New Therapies for Asthma Including Omalizumab and Anti-Cytokine Therapies Marsha Dangler, PharmD, BCACP Clinical Pharmacy Specialist James H. Quillen VA Medical
More informationPulmonary Diseases. Lung Disease: Pathophysiology, Medical and Exercise Programming. Overview of Pathophysiology
Lung Disease: Pathophysiology, Medical and Exercise Programming Overview of Pathophysiology Ventilatory Impairments Increased airway resistance Reduced compliance Increased work of breathing Ventilatory
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Remit / Appraisal objective: Final scope To appraise the clinical and cost effectiveness of
More informationVPM 152. INFLAMMATION: Chemical Mediators
General Pathology VPM 152 INFLAMMATION: Chemical Mediators CHEMICAL MEDIATORS OF INFLAMMATION Definition: any messenger that acts on blood vessels, inflammatory cells or other cells to contribute to an
More informationTHE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points
December 2008 (Vol. 1, Issue 3, pages 36-40) THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES By Sophie Lotersztajn, PhD, Ariane Mallat, MD, PhD Inserm U841, Hôpital Henri Mondor,
More informationDiabetic Ketoacidosis: When Sugar Isn t Sweet!!!
Diabetic Ketoacidosis: When Sugar Isn t Sweet!!! W Ricks Hanna Jr MD Assistant Professor of Pediatrics University of Tennessee Health Science Center LeBonheur Children s Hospital Introduction Diabetes
More informationAtrial Fibrillation in the ICU: Attempting to defend 4 controversial statements
Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Salmaan Kanji, Pharm.D. The Ottawa Hospital The Ottawa Hospital Research Institute Conflict of Interest No financial, proprietary
More informationIntroduction. Pathogenesis of type 2 diabetes
Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic
More informationPULMONARY HYPERTENSION. Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana
PULMONARY HYPERTENSION Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana What is Pulmonary Hypertension? What is normal? Pulmonary artery systolic pressure
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationACLS PHARMACOLOGY 2011 Guidelines
ACLS PHARMACOLOGY 2011 Guidelines ADENOSINE Narrow complex tachycardias or wide complex tachycardias that may be supraventricular in nature. It is effective in treating 90% of the reentry arrhythmias.
More informationRestore and Maintain treatment protocol
Restore and Maintain treatment protocol Combating inflammation through the modulation of eicosanoids Inflammation Inflammation is the normal response of a tissue to injury and can be triggered by a number
More informationMedical Direction and Practices Board WHITE PAPER
Medical Direction and Practices Board WHITE PAPER Use of Pressors in Pre-Hospital Medicine: Proper Indication and State of the Science Regarding Proper Choice of Pressor BACKGROUND Shock is caused by a
More informationCENTER FOR DRUG EVALUATION AND RESEARCH
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 205029Orig1s000 SUMMARY REVIEW Cross Discipline Team Leader Review 4. Nonclinical Pharmacology/Toxicology In their review of the original application,
More informationTests. Pulmonary Functions
Pulmonary Functions Tests Static lung functions volumes Dynamic lung functions volume and velocity Dynamic Tests Velocity dependent on Airway resistance Resistance of lung tissue to change in shape Dynamic
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More informationVersion 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen
Version 1 2015 Module guide International Master Program Cardiovascular Science University of Göttingen Part 1 Theoretical modules Synopsis The Master program Cardiovascular Science contains four theoretical
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationNutritional Support of the Burn Patient
Nutritional Support of the Burn Patient Objectives To understand the principles of normal nutrient utilization and the abnormalities caused by burn injury To be able to assess nutrient needs To be able
More informationChapter 16. Learning Objectives. Learning Objectives 9/11/2012. Shock. Explain difference between compensated and uncompensated shock
Chapter 16 Shock Learning Objectives Explain difference between compensated and uncompensated shock Differentiate among 5 causes and types of shock: Hypovolemic Cardiogenic Neurogenic Septic Anaphylactic
More informationInfluenza (Flu) Influenza is a viral infection that may affect both the upper and lower respiratory tracts. There are three types of flu virus:
Respiratory Disorders Bio 375 Pathophysiology General Manifestations of Respiratory Disease Sneezing is a reflex response to irritation in the upper respiratory tract and is associated with inflammation
More informationScottish Medicines Consortium
Scottish Medicines Consortium sildenafil citrate 20mg tablets (Revatio ) No. (235/06) Pfizer New indication 6 January 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationCompare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma
Chapter 31 Drugs Used to Treat Lower Respiratory Disease Learning Objectives Describe the physiology of respirations Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis,
More informationSepsis: Identification and Treatment
Sepsis: Identification and Treatment Daniel Z. Uslan, MD Associate Clinical Professor Division of Infectious Diseases Medical Director, UCLA Sepsis Task Force Severe Sepsis: A Significant Healthcare Challenge
More informationMECHINICAL VENTILATION S. Kache, MD
MECHINICAL VENTILATION S. Kache, MD Spontaneous respiration vs. Mechanical ventilation Natural spontaneous ventilation occurs when the respiratory muscles, diaphragm and intercostal muscles pull on the
More informationNO More Heart Disease
NO More Heart Disease Nitric Oxide Information NO is one of the simplest molecules in biology, comprised of just two atoms one atom of nitrogen (N) and one of oxygen (O). Through NO s structure is simple,
More informationUpdate on Small Animal Cardiopulmonary Resuscitation (CPR)- is anything new?
Update on Small Animal Cardiopulmonary Resuscitation (CPR)- is anything new? DVM, DACVA Objective: Update on the new Small animal guidelines for CPR and a discussion of the 2012 Reassessment Campaign on
More informationObjectives COPD. Chronic Obstructive Pulmonary Disease (COPD) 4/19/2011
Objectives Discuss assessment findings and treatment for: Chronic Obstructive Pulmonary Disease Bronchitis Emphysema Asthma Anaphylaxis Other respiratory issues Provide some definitions Chronic Obstructive
More informationVascular Effects of Caffeine
Vascular Effects of Caffeine John P. Higgins MD, MBA, MPHIL, FACC, FACP, FAHA, FACSM, FASNC, FSGC Director of Exercise Physiology Memorial Hermann Sports Medicine Institute Chief of Cardiology, Lyndon
More informationDecreasing Sepsis Mortality at the University of Colorado Hospital
Decreasing Sepsis Mortality at the University of Colorado Hospital Maureen Dzialo, RN, BSN - Nurse Manager, Cardiac Intensive Care Unit Olivia Kerveillant, RN Clinical Nurse III, Medical Intensive Care
More informationRELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010
RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines
More informationCare Pathway for the Administration of Intravenous Iron Sucrose (Venofer )
Departments of Haematology, Nephrology and Pharmacy Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer ) [Care Pathway Review Date] Guidance for use This Care Pathway is intended
More informationPHENYLEPHRINE HYDROCHLORIDE INJECTION USP
PRESCRIBING INFORMATION PHENYLEPHRINE HYDROCHLORIDE INJECTION USP 10 mg/ml Sandoz Canada Inc. Date of Preparation: September 1992 145 Jules-Léger Date of Revision : January 13, 2011 Boucherville, QC, Canada
More informationPreoperative Laboratory and Diagnostic Studies
Preoperative Laboratory and Diagnostic Studies Preoperative Labratorey and Diagnostic Studies The concept of standardized testing in all presurgical patients regardless of age or medical condition is no
More informationType II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease
Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University
More informationCHAPTER 1: THE LUNGS AND RESPIRATORY SYSTEM
CHAPTER 1: THE LUNGS AND RESPIRATORY SYSTEM INTRODUCTION Lung cancer affects a life-sustaining system of the body, the respiratory system. The respiratory system is responsible for one of the essential
More informationThe patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization.
Emergency Room Asthma Management Algorithm The Emergency Room Asthma Management Algorithm is to be used for any patient seen in the Emergency Room with the diagnosis of asthma. (The initial history should
More informationCommon Ventilator Management Issues
Common Ventilator Management Issues William Janssen, M.D. Assistant Professor of Medicine National Jewish Health University of Colorado Denver Health Sciences Center You have just admitted a 28 year-old
More informationMarilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL
Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT
More informationOxygen Therapy. Oxygen therapy quick guide V3 July 2012.
PRESENTATION Oxygen (O 2 ) is a gas provided in a compressed form in a cylinder. It is also available in a liquid form. It is fed via a regulator and flow meter to the patient by means of plastic tubing
More informationHyperbaric Oxygen Therapy WWW.RN.ORG
Hyperbaric Oxygen Therapy WWW.RN.ORG Reviewed September, 2015, Expires September, 2017 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2015 RN.ORG, S.A.,
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Pulmonary Arterial Hypertensive (PAH) agents Rx.01.83 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product
More informationBlood Transfusion. There are three types of blood cells: Red blood cells. White blood cells. Platelets.
Blood Transfusion Introduction Blood transfusions can save lives. Every second, someone in the world needs a blood transfusion. Blood transfusions can replace the blood lost from a serious injury or surgery.
More informationJeopardy Topics: THE CLOT STOPS HERE (anticoagulants) SUGAR, SUGAR, HOW D YOU GET SO HIGH (insulins)
Jeopardy Topics: THE CLOT STOPS HERE (anticoagulants) SUGAR, SUGAR, HOW D YOU GET SO HIGH (insulins) I HEAR YA KNOCKING BUT YOU CAN T COME IN (electrolytes) TAKE MY BREATH AWAY (Opiates-morphine) OUT WITH
More informationRESPIRATORY VENTILATION Page 1
Page 1 VENTILATION PARAMETERS A. Lung Volumes 1. Basic volumes: elements a. Tidal Volume (V T, TV): volume of gas exchanged each breath; can change as ventilation pattern changes b. Inspiratory Reserve
More informationNursing college, Second stage Microbiology Dr.Nada Khazal K. Hendi L14: Hospital acquired infection, nosocomial infection
L14: Hospital acquired infection, nosocomial infection Definition A hospital acquired infection, also called a nosocomial infection, is an infection that first appears between 48 hours and four days after
More informationSan Diego Stem Cell Treatment Center Frequently Asked Questions
San Diego Stem Cell Treatment Center Frequently Asked Questions What is a Stem Cell? A stem cell is basically any cell that can replicate and differentiate. This means the cell can not only multiply, but
More informationOxygen - update April 2009 OXG
PRESENTATION Oxygen (O 2 ) is a gas provided in compressed form in a cylinder. It is also available in liquid form, in a system adapted for ambulance use. It is fed via a regulator and flow meter to the
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationDepartment of Surgery
What is emphysema? 2004 Regents of the University of Michigan Emphysema is a chronic disease of the lungs characterized by thinning and overexpansion of the lung-like blisters (bullae) in the lung tissue.
More informationExtracorporeal Life Support Organization (ELSO) Guidelines for Neonatal Respiratory Failure
Extracorporeal Life Support Organization (ELSO) Guidelines for Neonatal Respiratory Failure Introduction This neonatal respiratory failure guideline is a supplement to ELSO s General Guidelines for all
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More informationTuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More informationAPPENDIX B SAMPLE PEDIATRIC CRITICAL CARE NURSE PRACTITIONER GOALS AND OBJECTIVES
APPENDIX B SAMPLE PEDIATRIC CRITICAL CARE NURSE PRACTITIONER GOALS AND OBJECTIVES The critical care nurse practitioner orientation is an individualized process based on one s previous experiences and should
More informationPrevention of Acute COPD exacerbations
December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal
More informationACID-BASE DISORDER. Presenter: NURUL ATIQAH AWANG LAH Preceptor: PN. KHAIRUL BARIAH JOHAN
ACID-BASE DISORDER Presenter: NURUL ATIQAH AWANG LAH Preceptor: PN. KHAIRUL BARIAH JOHAN OBJECTIVES OF PRESENTATION 1. To refresh knowledge of acid-base disorders 2. To evaluate acid-base disorders using
More informationAsthma in Infancy, Childhood and Adolescence. Presented by Frederick Lloyd, MD Palo Alto Medical Foundation Palo Alto, California
Asthma in Infancy, Childhood and Adolescence Presented by Frederick Lloyd, MD Palo Alto Medical Foundation Palo Alto, California Major Health Problem in Childhood Afflicts 2.7 million children in the USA
More informationX-Plain Abdominal Aortic Aneurysm Vascular Surgery Reference Summary
X-Plain Abdominal Aortic Aneurysm Vascular Surgery Reference Summary Ballooning of the aorta, also known as an "abdominal aortic aneurysm," can lead to life threatening bleeding. Doctors may recommend
More informationFocus on Preventing Disease. keeping an eye on a healthy bottom line. Cattle Industry
Focus on Preventing Disease keeping an eye on a healthy bottom line Cattle Industry Multimin + VACCINES : University OF FLORIDA study data Study 1 Effect of injectable trace minerals on the humoral immune
More informationLaboratory Monitoring of Adult Hospital Patients Receiving Parenteral Nutrition
Laboratory Monitoring of Adult Hospital Patients Receiving Parenteral Nutrition Copy 1 Location of copies Web based only The following guideline is for use by medical staff caring for the patient and members
More informationCoronary Artery Disease leading cause of morbidity & mortality in industrialised nations.
INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.
More informationRegulation of Metabolism. By Dr. Carmen Rexach Physiology Mt San Antonio College
Regulation of Metabolism By Dr. Carmen Rexach Physiology Mt San Antonio College Energy Constant need in living cells Measured in kcal carbohydrates and proteins = 4kcal/g Fats = 9kcal/g Most diets are
More informationINTRODUCTION TO EECP THERAPY
INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and
More informationBlood Transfusion. Red Blood Cells White Blood Cells Platelets
Blood Transfusion Introduction Blood transfusions are very common. Each year, almost 5 million Americans need a blood transfusion. Blood transfusions are given to replace blood lost during surgery or serious
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationProtocol in depth Asthma/COPD. daniel.dunham@clemc.us
Protocol in depth Asthma/COPD daniel.dunham@clemc.us Asthma/COPD Narrowing of airways (an H4 histamine response causing inflammation and mucous production), leading to wheezing on inspiration and exhalation.
More informationBSc in Medical Sciences with PHARMACOLOGY
BSc in Medical Sciences with PHARMACOLOGY Course Director Dr Christopher John Module Leaders Dr Robert Dickinson (Module 1) Dr Anabel Varela Carver (Module 2) Dr Sohag Saleh (Module 3) Course Administrator
More informationCrash Cart Drugs Drugs used in CPR. Dr. Layla Borham Professor of Clinical Pharmacology Umm Al Qura University
Crash Cart Drugs Drugs used in CPR Dr. Layla Borham Professor of Clinical Pharmacology Umm Al Qura University Introduction A list of the drugs kept in the crash carts. This list has been approved by the
More informationJames F. Kravec, M.D., F.A.C.P
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
More informationAcute on Chronic Liver Failure: Current Concepts. Disclosures
Acute on Chronic Liver Failure: Current Concepts Vandana Khungar, MD MSc Assistant Professor of Medicine University of Pennsylvania, Perelman School of Medicine September 20, 2015 None to declare Disclosures
More informationMethyl groups, like vitamins, are
Methyl groups are essential for the body to function properly and must be obtained from the diet The need for methyl groups increases under stress Chapter 11 Betaine a new B vitamin Methyl groups reduce
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationCOPD PROTOCOL CELLO. Leiden
COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on
More informationAtrial Fibrillation Management Across the Spectrum of Illness
Disclosures Atrial Fibrillation Management Across the Spectrum of Illness NONE Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University Objectives AF Discuss the pathophysiology, diagnosis,
More informationAnti-Atheroscrerotic Drugs
Anti-Atheroscrerotic Drugs Masuko Ushio-Fukai, PhD, FAHA Dept. of Pharmacology University of Illinois at Chicago Anti-Atherogenic Drugs: Treatment of Hyperlipidemias Knowledge Objectives: 1) Know the mechanism
More informationPotulaca (Portulaca oleracea) detergent and other formulations that disrupt the active anthraquinones by regulating the Nitric
Natural effective support for acne, oily and inflamed skin care At the heart of Frutarom's TopicRange for oily and acne skin problems, we focus Z-Care - a botanical blend based on traditions of Chinese
More informationChronic Critical Illness: Can it be prevented? Carmen C Polito, MD Pulmonary & Critical Care Medicine Emory University Atlanta, GA cpolito@emory.
Chronic Critical Illness: Can it be prevented? Carmen C Polito, MD Pulmonary & Critical Care Medicine Emory University Atlanta, GA cpolito@emory.edu Data free zone Disclosures A (Very) Old Case 65 year-old
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More information